Clinicopathologic correlates of loss of heterozygosity in Wilms' tumor: A preliminary analysis

Medical and Pediatric Oncology

Volumn 27, Issue 5, 1996, Pages 429-433

  Grundy, Paul ^a,b   Telzerow, Perry ^b   Moksness, Jami ^c   Breslow, Norman E ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

loss of heterozygosity; nephrogenic rests; WT1 and WT2

Indexed keywords

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHROMOSOME 11P; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME LOSS; HUMAN; HUMAN TISSUE; HYPERPLASIA; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; ONSET AGE; PRIORITY JOURNAL;

AGE FACTORS; ANAPLASIA; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 16; DISEASE-FREE SURVIVAL; DNA; GENE DELETION; GENES, WILMS TUMOR; GENOTYPE; HETEROZYGOTE; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; PHENOTYPE; SURVIVAL RATE; TREATMENT OUTCOME; WILMS TUMOR;

EID: 0029838115     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199611)27:5<429::AID-MPO7>3.0.CO;2-O     Document Type: Article

References (19)

1. Wadey RB, Pal N, Buckle B, Yeomans E, Pritchard J, Cowell JK: Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11. Oncogene 5:901-907, 1990.
2. Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin BC, Kalbakji A, Cavenee WK: Familial Weidemann-Beckwith syndrome and a second Wilms' tumor locus both map to 11p15.5. Am J Hum Genet 44:711-719, 1989.
3. Maw MA, Grundy PE, Millow LJ, Eccles MR, Dunn RS, Smith PJ, Feinberg AP, Law DJ, Paterson MC, Telzerow PE, Callen DF, Thompson AD, Richards RI, Reeve AE: A third Wilms' tumor locus on chromosome 16q. Cancer Res 52:3094-3098, 1992.
4. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC: Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54:2331-2333, 1994.
5. Mannens M, Slater RM, Heyting C, Blick J, De Kraker J, Coad N, De Pagter-Holthuizen P, Pearson PL: Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumors. Hum Genet 81:41-48, 1988.
6. Reeve AE, Sih SA, Raizis AM, Feinberg AP: Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cell Biol 9:1799-1803, 1989.
7. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362:749-751, 1993.
8. Beckwith JB, Kiviat NB, Bonadio JF: Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Perspect Pediatr Pathol 10:1-36, 1990.
9. D'Angio GJ, Breslow N, Beckwith B, Evans A, Baum E, DeLorimier A, Fernbach D, Hrabovsky E, Jones B, Kelalis P, Othersen B, Tefft M, Thomas PRM: Treatment of Wilms' tumor. Results of the third national Wilms' tumor study. Cancer 64:349-360, 1989.
10. Beckwith JB, Palmer NF: Histopathology and prognosis of Wilms' tumor. Cancer 41:1937-1948, 1978.
11. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Statist Soc [A] 135:185-192, 1972.
12. Cox DR: Regression models and life tables. J R Stat Soc [B] 34:187-220, 1972.
13. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784, 1983.
14. Varanasi R, Bardeesy N, Ghahremani M, Petruzzi M-J, Nowak N, Adam MA, Grundy P, Shows TB, Pelletier J: Fine structure analysis of the WT1 gene in sporadic Wilms' tumor. Proc Natl Acad Sci USA 91:3554-3558, 1994.
15. Gessler M, Konig A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, Cavenee W, Bruns G: Infrequent mutation of the WT1 gene in 77 Wilms' tumors. Hum Mutat 3:212-222, 1994.
16. Mannens M, Devilee P, Bliek J, Mandjes I, De Kraker J, Heyting C, Slater RM, Westerveld A: Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11. Cancer Res 50:3279-3283, 1990.
17. Coppes MJ, Bonetta L, Huang A, Hoban P, Chilton-MacNeill S, Campbell CE, Weksberg R, Yeger H, Reeve AE, Williams BRG: Loss of heterozygosity mapping in Wilms' tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination. Genes Chromosomes Cancer 5:326-334, 1992.
18. Bardeesy N, Falkoff D, Petruzzi M-J, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet 7:91-97, 1994.
19. Malkin D, Sexsmith E, Yeger H, Williams BRG, Coppes MJ: Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 54:2077-2079, 1994.